Steven E. Nissen MD is Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic. Dr. Nissen came to the Cleveland Clinic in 1992. He served for 9 years as Vice-Chairman of the Department and five years as Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), an organization that directs multicenter clinical trials. In 2006, he was appointed Chairman. National leadership positions include a term as President of the American College of Cardiology (ACC), the professional society representing American cardiologists (March 2006 to March 2007). Dr. Nissen has served numerous ACC committees and working groups including Education Committee, Annual Scientific Session Planning Committee, and 2 terms as Board of Trustee. Steven Nissen earned his medical degree from the Michigan University School of Medicine in Ann Arbor. He completed Internal Medicine internship and residency at the University of California, Davis in Sacramento, and Cardiology Fellowship at the University of Kentucky Medical Center in Lexington. Dr. Nissen’s research during the last two decades has focused on application of intravascular ultrasound (IVUS) imaging to the assessment of progression and regression of coronary atherosclerosis. Contributions to scientific literature include being author/coauthor of more than 350 journal articles and 60 book chapters. As a physician/scientist, Dr. Nissen consults for many pharmaceutical companies on the development of new therapies for cardiovascular disease, but maintains a longstanding personal policy of requiring companies to donate all related honoraria directly to charity so that he receives neither income, nor a tax deduction. In recent years, he has also written extensively on the subject of drug safety. In 2001, he was co-author of the first manuscript that raised concerns about the safety of rofecoxib (Vioxx), which was withdrawn from the market 3 years later. In 2005, he re-analyzed data submitted to the Food and Drug Administration (FDA) to support approval of muraglitazar, a new agent to treat diabetes and lipid disorders. Despite a recommendation by an FDA Advisory Panel to approve this new agent, Dr. Nissen’s study reported that muraglitazar doubled the risk of major adverse cardiovascular outcomes and the Agency halted approval. In 2007, he was the author of a manuscript that demonstrated that the widely used diabetes drug rosiglitazone (Avandia™) raised the risk of myocardial infarction, resulting in a “black box’ warning by the FDA 6 months later. Dr. Nissen served as a member of the CardioRenal Advisory Panel of Food and Drug Administration (FDA) for 5 years, and as Chairman of the final year of his membership. He continues to serve as Advisor to several FDA committees as a Special Government Employee. In July 2008, while serving as guest member of the Endocrine and Metabolism Advisory Panel, Dr. Nissen recommended a new approach to approval of diabetes drugs, which was ultimately adopted by the Agency in November 2008. Steven Nissen is also known for his role in public policy discussions, particularly in the area of drug safety. He has testified in both the Senate (Health Education and Labor Committee) and House of Representatives (Energy and Commerce Committee) on the need to reform the Food and Drug Administration (FDA). He was actively involved in discussions with Congress on the FDA Amendments Act of 2007 that added additional regulatory authority for the Agency. Professor Steven Nissen was selected for the Outstanding Scientist Award by the Cleveland Clinic in 2004. Cleveland Clinic Cardiovascular Medicine Fellows have awarded him the Outstanding Teaching Award, an annual recognition, on 3 occasions. He also received Award for Outstanding Contributions to Cardiovascular Research from the Gill Heart Institute of the University of Kentucky in 2004. Other awards include “Best Doctors” 2008 by Cleveland Magazine, “One of 40 most influential persons in the City of Cleveland” 2008 Cleveland Magazine, Country’s 30 “most powerful forces in Business and Finance” 2007 Smart Money Magazine, 100 Most Influential People, Scientists and Thinkers 2007 TIME Magazine.